Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty

Circulation

Volumn 100, Issue 1, 1999, Pages 21-26

  Tsuchikane, Etsuo ^a   Fukuhara, Atsunori ^a   Kobayashi, Tohru ^a   Kirino, Motohiro ^a   Yamasaki, Keita ^a   Kobayashi, Tomoko ^a   Izumi, Masahiro ^a   Otsuji, Satoru ^a   Tateyama, Hitone ^a   Sakurai, Makoto ^a   Awata, Nobuhisa ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Angioplasty; Platelet aggregation inhibitors; Restenosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL;

ADULT; AGED; ARTICLE; ATHERECTOMY; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; SKIN TOXICITY;

EID: 0033529402     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.1.21     Document Type: Article

References (32)

1. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-371.
2. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94: 35-43.
3. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and role of intimai hyperplasia. Circulation. 1989;79:1374-1387.
4. McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty: pathiophysiology and prevention. N Engl J Med. 1988;318: 1734-1737.
5. Ferns GA, Raines EW, Sprugel KH, Montani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle cell accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
6. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
7. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318:1714-1719.
8. Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y. Nakagawa K. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II: 6-[3-(1-Cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull. 1983;31: 1151-1157.
9. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung/Drug Res. 1985;35:1144-1149.
10. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effect of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
11. Ohashi S, Iwatani Y, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung/Drug Res. 1985;35: 1203-1208.
12. Matsumoto Y, Tani T, Watanabe K, Kimura Y. Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats. Jpn J Pharmacol. 1992;58:284.
13. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makitani S, Sakaguchi S, Yoshioka T, Ohishi H, Kimura Y, Yoshikawa T. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Invest Radiol. 1995;30:532-537.
14. Tsuchikane E, Katoh O, Sumitsuji S, Fukuhara A, Funamoto M, Otsuji S, Tateyama H, Awata N, Kobayashi T. Impact of cilostazol on intimai proliferation after directional coronary atherectomy. Am Heart J. 1998; 135:495-502.
15. Yamasaki M, Hara K, Ikari Y, Kobayashi N, Kozuma K, Ohmoto Y, Oh-hashi Y, Ako J, Nakajima H, Chiku N, Saeki F, Tamura T. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 1998;44:387-391.
16. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther. 1997;19:1058-1066.
17. Nakamura T, Tsuchikane E, Sumitsuji S, Awata N, Kobayashi T. Impact of cilostazol on neointimal proliferation following Palmaz-Schatz stent implantation: a prospective randomized trial. J Am Coll Cardiol. 1998; 31:404A. Abstract.
18. Ikeda Y, Kikuchi M, Murakami H, Satoh K, Murata M, Watanabe K, Ando Y. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Arzneimittelforschung/Drug Res. 1987;37:563-566.
19. Yasunaga K, Mase K. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung/Drug Res. 1985;35:1189-1192.
20. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-686.
21. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, Sato S, Unemi F, Kimura Y. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res. 1990;57: 617-623.
22. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
23. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900-906.
24. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48: 827-835.
25. Morisaki N, Kanzaki T, Motoyama N, Saito Y, Yoshida S. Cell cycle-dependent inhibition of DNA synthesis by prostaglandin 12 in cultured rabbit aortic smooth muscle cells. Atherosclerosis. 1988;71:165-171.
26. Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′5′-monophosphate. Science. 1993;262:1065-1069.
27. Cook SJ, McCorrnick F. Inhibition by cAMP of Ras-dependent activation of raf. Science. 1993;262:1069-1072.
28. Nakamura T, Hagiya M, Nishizawa T, Seki T, Shimonishi M, Sugiura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440-443.
29. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, Yo Y, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes. 1997;46:138-142.
30. Morishita R, Higaki J, Hayashi S, Yo Y, Aoki M, Moriguchi A, Matsushita H, Matsumoto K, Nakamura T, Ogihara T. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia. 1997;40:1053-1061.
31. Ochiai M, Isshiki T, Sato T. Use of cilostazol, a novel antiplatelet agent, in a Palmaz-Schatz stenting regimen. Am J Cardiol. 1997;79:1471-1474.
32. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation. 1996;94: 1247-1254.